Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR4 | Q5NUL3 | 5/20 | 0.40 |
| ▸ | PPARG | P37231 | 2/20 | 0.36 |
| ▸ | PPARA | Q07869 | 1/20 | 0.36 |
| ▸ | S1PR1 | P21453 | 4/20 | 0.35 |
| ▸ | S1PR3 | Q99500 | 3/20 | 0.35 |
| ▸ | S1PR5 | Q9H228 | 3/20 | 0.35 |
| ▸ | CA1 | P00915 | 2/20 | 0.35 |
| ▸ | CA2 | P00918 | 2/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.33 |
| ▸ | NAAA | Q02083 | 1/20 | 0.33 |
| ▸ | ASAH1 | Q13510 | 1/20 | 0.33 |
| ▸ | CSF1R | P07333 | 1/20 | 0.33 |
| ▸ | SLC6A9 | P48067 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19804686 | 0.94 | FFAR4 (0.38) | FFAR4PPARGPPARAS1PR1S1PR3 | |
| SCHEMBL19804621 | 0.94 | FFAR4 (0.38) | FFAR4PPARGPPARAS1PR1S1PR3 | |
| SCHEMBL19804809 | 0.92 | FFAR4 (0.44) | FFAR4PPARGPPARAS1PR1S1PR3 | |
| SCHEMBL19804523 | 0.92 | FFAR4 (0.44) | FFAR4PPARGPPARAS1PR1S1PR3 | |
| SCHEMBL19804644 | 0.89 | FFAR4 (0.43) | FFAR4PPARGPPARAS1PR1S1PR3 | |
| SCHEMBL19804514 | 0.89 | CA1 (0.38) | FFAR4PPARGPPARAS1PR1S1PR3 | |
| SCHEMBL19804632 | 0.88 | FFAR4 (0.43) | FFAR4PPARGPPARAS1PR1S1PR3 | |
| SCHEMBL19797113 | 0.87 | SPHK1 (0.37) | FFAR4CA1CA2CYP2C9 | |
| SCHEMBL19804355 | 0.86 | FFAR4 (0.38) | FFAR4PPARGPPARAS1PR1S1PR3 | |
| SCHEMBL19804498 | 0.84 | SLC6A9 (0.40) | PPARGPPARACA1CA2CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180023001-A1 | COMPOUND HAVING POLYMERIZABLE GROUP, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE | JNC CORPORATION (JP) | 2018-01-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180023001-A1 | COMPOUND HAVING POLYMERIZABLE GROUP, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE | SP1, C1S, AP3D1 | FFAR4 1715/4885PPARG 3314/4885PPARA 3672/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.